SILLAJEN BIOTHERAPEUTICS INC has a total of 28 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2003. It filed its patents most often in Australia, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are VECTOGEN PTY LTD, WYETH FARMA SA and BOEHRINGER INGELHEIM VETMEDICA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 9 | |
#2 | United States | 9 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Hungary | 2 | |
#5 | Japan | 2 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Agriculture |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Electrotherapy | |
#6 | Analysing materials | |
#7 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Kirn David | 27 |
#2 | Breitbach Caroline | 9 |
#3 | Bell John | 6 |
#4 | Thorne Steve H | 3 |
#5 | Lee Yu Kyoung | 3 |
#6 | Hwang Tae-Ho | 3 |
#7 | Kim Mi-Kyung | 3 |
#8 | Caroline Breitbach | 2 |
#9 | Moon Anne | 2 |
#10 | David Kirn | 1 |
Publication | Filing date | Title |
---|---|---|
AU2012261681A1 | Methods and compositions concerning poxviruses and cancer | |
AU2012244210A1 | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses | |
AU2012294606A1 | Methods and compositions for production of vaccinia virus | |
CN107303302A | Oncolytic vaccinia virus combines cancer therapy | |
AU2006287441A1 | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |